Clinical Trial Update: EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ferric carboxymaltose on exercise capacity and cardiac function in iron-deficient chronic heart failure patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Heart Failure
• Iron Deficiency
• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Vifor Pharma | Conditions: Chronic Heart Failure, Iron Deficiency | Phase 3 | Status: TERMINATED